Complete mucosal restoration 4
High rates of ulcer healing
Significant relief in non-ulcer dyspepsia 2
First line therapy in GERD during pregnancy 3
DESCRIPTION:
Ulsanic contains sucralfate, a non-systemic cytoprotective agent for the treatment of acid peptic disorders. Chemically it is a basic aluminium salt of sucrose octasulfate.
MECHANISM OF ACTION :
In the presence of acid-induced iamage, pepsin mediated hydrolysis of mucosal proteins contributes to mucosal erosions and ulceration it undergoes extensive cross linking and polymerization to produce a viscous, sticky gelthat adheres strongly to epithelial cells and even nore strongly to ulcer craters foras long as 6 to 8 hours after a single dose. In addition inhibition of hydrolysis of mucosal proteins >y pepsin, Ulsanic has additional cytoprotective effects, including stimulation of local production of mucosal prostaglandin and spidermal growth factor (EGF) & basic fibroblast growth factor (bFGF). Ulsanic also binds bile salts, accounting for its use in some jatients with esophagitis or gastritis The layer of Ulsanic acts as a three-way barrier intensifying the mucosal resistance: It blocks he diffusion of gastric acid and pepsin to the ulcerated mucosa (anti-diffusion barrier.
THERAPEUTIC INDICATIONS:
Gastric and luodenal ulcer. Relapse prophylaxis of gastric and duodenal ulcer. Reflux esophagitis. Stress ulcer prophylaxis.
DOSAGE:
Duodenal jlcer: 2 Tablets Ulsanic 1GM twice a day or 2 teaspoonful Ulsanic (1GM susp.) twice a day. Gastric ulcer: 1 Tablet Ulsanic 1GM 3 to 4 imes a day. Or 1 teaspoonful Ulsanic( 1GM susp.) 3 to 4 times a day. Relapse prophylaxis of gastric and duodenal ulcer: 2 Tablets Jlsanic 1GM once a day or 2 teaspoonful ulsanic (1GM susp.) once a day.
Reflux esophagitis:
1 Tablet ulsanic 1GM 4 times a day or 1 easpoonful Ulsanic( 1GM susp.) 4 times a day. Stress ulcer prophylaxis: 1 tablet ulsanic 1GM every 4 hours or 1 teaspoonful Ulsanic 1 GM susp.) every 4 hours. For short-term treatment of gastric and duodenal ulcer. Ulsanic is best taken on an empty stomach. In i or 4 x 1 g administration, a single dose (1 g) is taken before meals: the 4th dose in the evening at bedtime, in 2 x 2 g administration me dose (2 g) is taken in the morning on rising and a dose in the evening at bedtime.
For short-term treatment of reflux esophagitis, n 4 x 1 g administration, a single dose (1 g) is taken after meals and at bedtime. WARNING AND SPECIAL PRECAUTIONS FOR USE: A/hen sucralfate isadministered orally, small amounts of aluminum are absorbed from the gastrointestinal tract. Patients with normal enal function receiving the recommended doses of sucralfate adequately excrete aluminum in the urine. Patients with renal dysfunction >r on dialysis have impaired excretion of absorbed aluminum. Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, jncephalopathy) have been described in patients with renal impairment.
"he blood concentration of aluminum, phosphate, calcium, alkaline phosphatase, etc., should be periodically measured. 3atients with swallowing difficulty: At the time of taking sucralfate, aspiration may occur in patients with swallowing difficulty. \DVERSE REACTIONS: Immune system disorders: Anaphylactic reaction.
Dermatological:
rash. Gastrointestinal: constipation, iry mouth, nausea. A few cases of bezoar have been reported in patients with the administration of Sucralfate suspension and enteral feeds by naso-gastric tube.
PREGNANCY AND LACTATION:
No teratogenic effects Pregnancy Category B. PRESENTATION: 1 Ulsanic 500 mg tablets: Pack of20 tablets. 2. Ulsanic 1G tablets: Pack of 10 tablets. 4. Ulsanic 1GM suspension: Bottle of 60 ml. Detailed precribing information available on rquest.
0 comments